The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection
Open accessAbstract
BACKGROUND & AIMS Tenofovir alafenamide (TAF) is a new prodrug of tenofovir developed to treat patients with chronic hepatitis B virus (HBV) infection at a lower dose than tenofovir disoproxil fumarate (TDF) through more efficient delivery of tenofovir to hepatocytes. In 48-week results from two ongoing, double-blind, randomized phase III trials, TAF was non-inferior to TDF in efficacy with improved renal and bone safety. We report 96-week outcomes for both trials. METHODS In two international trials, patients with chronic HBV infection were randomized 2:1 to receive 25 mg TAF or 300 mg TDF in a double-blinded fashion. One study enrolled HBeAg-positive patients and the other HBeAg-negative patients. We assessed efficacy in each study, and safety in the pooled population. RESULTS At week 96, the differences in the rates of viral suppression were similar in HBeAg-positive patients receiving TAF and TDF (73% vs. 75%, respectively, adjusted difference -2.2% (95% CI -8.3 to 3.9%; p = 0.47), and in HBeAg-negative patients receiving TAF and TDF (90% vs. 91%, respectively, adjusted difference -0.6% (95% CI -7.0 to 5.8%; p = 0.84). In both studies the proportions of patients with alanine aminotransferase above the upper limit of normal at baseline, who had normal alanine aminotransferase at week 96 of treatment, were significantly higher in patients receiving TAF than in those receiving TDF. In the pooled safety population, patients receiving TAF had significantly smaller decreases in bone mineral density than those receiving TDF in the hip (mean % change -0.33% vs. -2.51%; p <0.001) and lumbar spine (mean % change -0.75% vs. -2.57%; p <0.001), as well as a significantly smaller median change in estimated glomerular filtration rate by Cockcroft-Gault method (-1.2 vs. -4.8 mg/dl; p <0.001). CONCLUSION In patients with HBV infection, TAF remained as effective as TDF, with continued improved renal and bone safety, two years after the initiation of treatment. Clinicaltrials.gov number: NCT01940471 and NCT01940341. LAY SUMMARY At week 96 of two ongoing studies comparing the efficacy and safety of tenofovir alafenamide (TAF) to tenofovir disoproxil fumarate (TDF) for the treatment of chronic hepatitis B patients, TAF continues to be as effective as TDF with continued improved renal and bone safety. Registration: Clinicaltrials.gov number: NCT01940471 and NCT01940341.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
Lampertico, P., Agarwal, K., Berg, T., Buti, M., Janssen, H. L. A., Papatheodoridis, G., Zoulim, F., & Tacke, F. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.021 · Cited by 5,391
Self-citationAsian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
Sarin, S. K., Kumar, M., Lau, G. K., Abbas, Z., Chan, H. L. Y., Chen, C. J., Chen, D. S., Chen, H. L., Chen, P. J., Chien, R. N., et al. (2016) · Hepatology International · doi:10.1007/s12072-015-9675-4 · Cited by 2,550
Self-citationHepatitis B Virus Infection — Natural History and Clinical Consequences
Ganem, D., & Prince, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmra031087 · Cited by 2,357
AASLD guidelines for treatment of chronic hepatitis B
Terrault, N. A., Bzowej, N. H., Chang, K., Hwang, J. P., Jonas, M. M., & Murad, M. H. (2016) · Hepatology · doi:10.1002/hep.28156 · Cited by 2,006
Marcellin, P., Gane, E., Buti, M., Afdhal, N., Sievert, W., Jacobson, I. M., Washington, M. K., Germanidis, G., Flaherty, J. F., Schall, R. A., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61425-1 · Cited by 1,788
Self-citationFattovich, G., Bortolotti, F., & Donato, F. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.11.011 · Cited by 1,348
Buti, M., Gane, E., Seto, W. K., Chan, H. L. Y., Chuang, W.-L., Stepanova, T., Hui, A.-J., Lim, Y.-S., Mehta, R., Janssen, H. L. A., et al. (2016) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(16)30107-8 · Cited by 554
Self-citationTenofovir-Associated Kidney Toxicity in HIV-Infected Patients: A Review of the Evidence
Hall, A. M., Hendry, B. M., Nitsch, D., & Connolly, J. O. (2011) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2011.01.022 · Cited by 373
Lee, W. A., He, G.-X., Eisenberg, E., Cihlar, T., Swaminathan, S., Mulato, A., & Cundy, K. C. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.5.1898-1906.2005 · Cited by 338
Ruane, P. J., DeJesus, E., Berger, D., Markowitz, M., Bredeek, U. F., Callebaut, C., Zhong, L., Ramanathan, S., S. Rhee, M., Fordyce, M. W., et al. (2013) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3182965d45 · Cited by 302
Cited by
Jeng, W.-J., Papatheodoridis, G. V., & Lok, A. S. F. (2023) · The Lancet · doi:10.1016/s0140-6736(22)01468-4 · Cited by 561
Mayer, K. H., Molina, J.-M., Thompson, M. A., Anderson, P. L., Mounzer, K. C., De Wet, J. J., DeJesus, E., Jessen, H., Grant, R. M., Ruane, P. J., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31065-5 · Cited by 428
EASL Clinical Practice Guidelines on the management of hepatitis B virus infection
Cornberg, M., Sandmann, L., Jaroszewicz, J., Kennedy, P., Lampertico, P., Lemoine, M., Lens, S., Testoni, B., Lai-Hung Wong, G., & Russo, F. P. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.03.018 · Cited by 437
Cornberg, M., Lok, A. S.-F., Terrault, N. A., Zoulim, F., Berg, T., Brunetto, M. R., Buchholz, S., Buti, M., Chan, H. L. Y., Chang, K.-M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.11.003 · Cited by 366
Self-citationaMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis
Fan, R., Papatheodoridis, G., Sun, J., Innes, H., Toyoda, H., Xie, Q., Mo, S., Sypsa, V., Guha, I. N., Kumada, T., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.07.025 · Cited by 364
Self-citation
Metadata
- Authors
- Agarwal, K., Brunetto, M., Seto, W. K., Lim, Y.-S., Fung, S., Marcellin, P., Ahn, S. H., Izumi, N., Chuang, W., Bae, H., Sharma, M., Janssen, H. L. A., Pan, C. Q., Çelen, M. K., Furusyo, N., Shalimar, D., Yoon, K. T., Trinh, H., Flaherty, J. F., Gaggar, A., Lau, A. H., Cathcart, A. L., Lin, L., Bhardwaj, N., Suri, V., Mani Subramanian, G., Gane, E. J., Buti, M., & Chan, H. L. Y.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2018-04
- Volume
- 68
- Issue
- 4
- Pages
- 672-681
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2782856081
- Cited by
- 428
- References
- 28
- FWCI
- 30.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. https://app.cochat.ai/papers/10.1016/j.jhep.2017.11.039
- The paper
- Agarwal, K., Brunetto, M., Seto, W. K., Lim, Y.-S., Fung, S., Marcellin, P., Ahn, S. H., Izumi, N., Chuang, W., Bae, H., Sharma, M., Janssen, H. L. A., Pan, C. Q., Çelen, M. K., Furusyo, N., Shalimar, D., Yoon, K. T., Trinh, H., Flaherty, J. F., . . . Chan, H. L. Y. (2018). 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2017.11.039
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.